2026 Global: Cardiac Marker Testing Market-Competitive Review (2032) report
Description
The 2026 Global: Cardiac Marker Testing Market-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiac marker testing market by geography and historical trend. The scope of the report extends to sizing of the cardiac marker testing market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Danaher Corporation, and Thermo Fisher Scientific Inc. lead the Cardiac Marker Testing Market, followed by bioMérieux SA, Becton Dickinson and Company, DiaSorin S.p.A., Bio-Rad Laboratories Inc., and QuidelOrtho Corporation as the ten major companies. These firms dominate through innovative assays for biomarkers like troponin, NT-proBNP, CK-MB, and BNP, enabling rapid diagnosis of myocardial infarction, heart failure, and atherosclerosis. Abbott excels in high-sensitivity troponin tests and point-of-care i-STAT systems, supporting early heart attack detection and global distribution. Roche advances NT-proBNP assays and integrated platforms for precise heart failure management, bolstered by R&D investments. Siemens Healthineers offers high-sensitivity troponin I with prognostic capabilities, enhancing risk stratification via automated analyzers.
Danaher Corporation, via subsidiaries Beckman Coulter and Radiometer, provides broad cardiac panels integrated into lab systems, while Thermo Fisher Scientific expands through acquisitions like Olink for novel protein discovery. bioMérieux innovates with SpinChip for near-patient whole-blood testing, challenging POC leaders in speed. Becton Dickinson contributes immunoassay kits, and DiaSorin specializes in chemiluminescence-based reagents for European markets. Bio-Rad Laboratories delivers reliable ELISA and chemiluminescence instruments, holding steady shares in consolidated segments. QuidelOrtho, post-merger, leads POC with Triage panels for troponin, CK-MB, myoglobin, BNP, and D-dimer, acquired from Alere.
Market concentration favors these multinationals, who control portfolios spanning lab analyzers, POC devices, and kits amid rising cardiovascular demands. Strategic moves like acquisitions and AI integration drive competition, with North America leading due to high disease prevalence and funding. Leaders prioritize sensitivity, workflow efficiency, and regulatory approvals, positioning for growth in decentralized testing.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for cardiac marker testing market by geography and historical trend. The scope of the report extends to sizing of the cardiac marker testing market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Abbott Laboratories, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Danaher Corporation, and Thermo Fisher Scientific Inc. lead the Cardiac Marker Testing Market, followed by bioMérieux SA, Becton Dickinson and Company, DiaSorin S.p.A., Bio-Rad Laboratories Inc., and QuidelOrtho Corporation as the ten major companies. These firms dominate through innovative assays for biomarkers like troponin, NT-proBNP, CK-MB, and BNP, enabling rapid diagnosis of myocardial infarction, heart failure, and atherosclerosis. Abbott excels in high-sensitivity troponin tests and point-of-care i-STAT systems, supporting early heart attack detection and global distribution. Roche advances NT-proBNP assays and integrated platforms for precise heart failure management, bolstered by R&D investments. Siemens Healthineers offers high-sensitivity troponin I with prognostic capabilities, enhancing risk stratification via automated analyzers.
Danaher Corporation, via subsidiaries Beckman Coulter and Radiometer, provides broad cardiac panels integrated into lab systems, while Thermo Fisher Scientific expands through acquisitions like Olink for novel protein discovery. bioMérieux innovates with SpinChip for near-patient whole-blood testing, challenging POC leaders in speed. Becton Dickinson contributes immunoassay kits, and DiaSorin specializes in chemiluminescence-based reagents for European markets. Bio-Rad Laboratories delivers reliable ELISA and chemiluminescence instruments, holding steady shares in consolidated segments. QuidelOrtho, post-merger, leads POC with Triage panels for troponin, CK-MB, myoglobin, BNP, and D-dimer, acquired from Alere.
Market concentration favors these multinationals, who control portfolios spanning lab analyzers, POC devices, and kits amid rising cardiovascular demands. Strategic moves like acquisitions and AI integration drive competition, with North America leading due to high disease prevalence and funding. Leaders prioritize sensitivity, workflow efficiency, and regulatory approvals, positioning for growth in decentralized testing.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.